Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
$87.00
$0.74(1.19%)
At close: 4:00 PM EST
$87.00
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$30.82 - $95.95
Previous CloseN/A
Volume41.94K
Average Volume (3M)528.29K
Market Cap
$3.30B
Enterprise ValueN/A
Total Cash (Recent Filing)$649.97M
Total Debt (Recent Filing)$30.92M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Mar 27, 2026EPS Estimate
-1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding37,384,630
10 Day Avg. Volume342,229
30 Day Avg. Volume528,287
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)3.95
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$115.00Price Target Upside32.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StrengthDisc Medicine has a strong financial position, ending the period with $615.9M in cash, cash equivalents, and investments, and extending its cash runway into 2029 after a public offering.
Market PotentialThe company is preparing for the commercial launch of bitopertin, which is expected to be a significant market opportunity, estimated at around $1 billion.
Regulatory ProgressThe submission of an NDA for bitopertin in EPP under the accelerated approval pathway and the potential for early approval highlights the FDA's recognition of the high unmet need and the drug's disease-modifying potential.
Bears Say
Clinical Trial ConcernsUpdates indicated Ph 1b hemoglobin responses for DISC-0974 in CKD-anemia were 'observed in only a subset of patients,' lowering our confidence in the indication.
Operational ChallengesDisc Medicine has never commercialized a product, which poses a risk for the successful launch and commercialization of bitopertin.
Regulatory ChallengesConcerns exist about the FDA's ability to meet the expedited review timeline due to recent leadership changes and workforce shortages.
Disc Medicine News
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $30.82 and its highest was $95.95 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $3.30B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Mar 27, 2026 which is in 139 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Nov 06, 2025. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.442 by -$0.328.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.63.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 37,384,630 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.442. Following the earnings report the stock price went down -1.483%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
Disc Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.00 (32.18% Upside)
$115.00 (32.18% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 607.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $74.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 11.9%
Last 30 Days ▲ 11.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.25%
12-Months-Change
Fundamentals
Return on Equity
-26.36%
Trailing 12-Months
Asset Growth
30.35%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine (IRON) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of hematologic diseases. The company's core products are designed to address conditions related to iron homeostasis, such as anemia and iron overload disorders. Disc Medicine aims to innovate within the hematology sector by developing drugs that can provide effective solutions for patients with unmet medical needs.
IRON Stock 12 Month Forecast
Average Price Target
$115.00
▲(32.18% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
5.23% Insiders
23.75% Mutual Funds
0.03% Other Institutional Investors
61.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---